BGI Genomics' Three-Stage Strategy: Leading in Application Services, Advancing into Core Technologies, and Expanding Ecosystem Initiatives

In December 2015, BGI Genomics, hailed as the “Tencent of the biological world,” confirmed its plan to list on the ChiNext board.

BGI Genomics, established in 1999, is the world’s largest genomics research and development organization. By forging extensive collaborations with stakeholders across the global industry chain through its worldwide network of branches, BGI Genomics applies cutting-edge multi-omics scientific achievements to fields such as medical health, agricultural breeding, and resource conservation.

In the healthcare sector, BGI Genomics pioneered the application of genetic testing technology to non-invasive prenatal screening and has actively expanded into fields such as oncology and assisted reproduction, becoming a leading provider of genetic testing technologies in China.

VCBeat maps out BGI Genomics’ growth trajectory, analyzing three key milestones and major strategic decisions in the company’s history:

• How Did BGI Seize the Opportunity of China’s Booming Market by Launching Application Services in 2010 on Its Path to Becoming the Leading Genetic Testing Company in China?




• In 2013, BGI Group Entered the Core Technology Layer: Why Did It Make a Major Push into the Core Segment of Genetic Testing—The R&D and Manufacturing of Upstream Sequencers?




• In 2015, it laid out its ecosystem extension layer by launching a genomic big data platform, partnering with Rongzhilian to develop a biological e-commerce business, and initiating a startup incubation and investment platform. Will BGI Genomics become the next BAT?

Industry professionals are welcome to add the author on WeChat (ID: yeyurenlei) to jointly discuss development trends in the healthcare industry.